Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.54 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.52 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.52 |
| ▸ | ADK | P55263 | 1/20 | 0.48 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.43 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14089358 | 1.00 | ADORA3 (0.57) | ADORA3ADORA2AADORA1ADORA2BPRMT5 | |
| SCHEMBL13598664 | 1.00 | ADORA3 (0.57) | ADORA3ADORA2AADORA1ADORA2BPRMT5 | |
| SCHEMBL13598817 | 1.00 | ADORA3 (0.57) | ADORA3ADORA2AADORA1ADORA2BPRMT5 | |
| SCHEMBL873612 | 0.91 | PRMT5 (0.58) | ADORA3ADORA2AADORA1ADORA2BPRMT5 | |
| SCHEMBL733384 | 0.91 | PRMT5 (0.58) | ADORA3ADORA2AADORA1ADORA2BPRMT5 | |
| SCHEMBL4432672 | 0.89 | ADORA3 (0.55) | ADORA3ADORA2AADORA1ADORA2BPRMT5 | |
| SCHEMBL13598665 | 0.89 | ADORA3 (0.55) | ADORA3ADORA2AADORA1ADORA2BPRMT5 | |
| SCHEMBL14089611 | 0.89 | ADORA3 (0.55) | ADORA3ADORA2AADORA1ADORA2BPRMT5 | |
| SCHEMBL14154308 | 0.88 | PRMT5 (0.48) | ADORA3ADORA2AADORA1ADORA2BPRMT5 | |
| SCHEMBL14154248 | 0.88 | ADK (0.47) | ADORA3ADORA2AADORA1ADORA2BPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147464-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-07-29 | — | — | US | claimed |
| US-7629320-B2 | Nucleoside derivatives for treating hepatitis C virus infection | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080249060-A1 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. | 2008-10-09 | — | — | US | disclosed |
| US-7425547-B2 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20040147464-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-07-29 | — | — | US | disclosed |
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | ADORA3 170/4885ADORA2A 174/4885ADORA1 522/4885 |
| US-20080249060-A1 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | HAVCR2, PNP, NTPCR | ADORA3 170/4885ADORA2A 174/4885ADORA1 522/4885 |
| US-20040147464-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | ADORA3 170/4885ADORA2A 174/4885ADORA1 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.